Survival outcomes in patients with muscle invasive bladder cancer undergoing radical vs. partial cystectomy

被引:3
|
作者
Chung, Rainjade [1 ]
Moran, George W. [1 ]
Movassaghi, Miyad [1 ]
Pohl, Daniel [1 ]
Ingram, Justin [1 ]
Lenis, Andrew T. [1 ]
Mckiernan, James M. [1 ]
Anderson, Christopher B. [1 ]
Faiena, Izak [1 ]
机构
[1] Columbia Univ, Med Ctr, Dept Urol, New York, NY 10027 USA
关键词
Partial cystectomy; Bladder cancer; Intravesical therapy; Recurrence; Survival; Multimodal therapy; UROTHELIAL CARCINOMA; THERAPY;
D O I
10.1016/j.urolonc.2023.04.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: While radical cystectomy (RC) is the standard of care for muscle invasive bladder cancer (MIBC), partial cystectomy (PC) is an effective alternative in select patients. We sought to examine differences in survival for RC and PC in a hospital-based registry. Material and Methods: We identified patients diagnosed with cT2-4 bladder cancer who underwent RC or PC from 2003 to 2015 in the National Cancer Database (NCDB). Using inverse probability treatment weighting (IPTW) to control for known confounders, we compared the primary outcome of overall survival (OS) in patients who underwent RC vs. PC. Kaplan-Meier survival analysis, univariable and multivariable Cox proportional hazards modeling were used. We performed a secondary survival analysis for a subcohort of patients with cT2, cN0, tumor size <= 5 cm, and no concurrent carcinoma in situ (CIS), who may be optimal candidates for PC. Results: A total of 22,534 patients met inclusion criteria, of which 6.9% (1,457) underwent PC. RC had longer median OS than PC (67.8 vs. 54.1 months) and on Cox regression analysis (HR 0.88, 95% CI, 0.80-0.95, P = 0.002). However, in our subcohort, there was no difference in OS between RC and PC (HR 1.02, 95% CI, 0.9-1.2, P = 0.74). PC was associated with increased time from surgery to any systemic therapy or death in the subcohort. Conclusions: Among patients with clinically organ-confined MIBC, PC appears to afford similar survival outcomes to RC in a large national data set. The safety and tolerability of PC may warrant consideration in highly selected patients. (c) 2023 Elsevier Inc. All rights reserved.
引用
收藏
页码:356.e11 / 356.e18
页数:8
相关论文
共 50 条
  • [1] SURVIVAL OUTCOMES IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER UNDERGOING RADICAL VS PARTIAL CYSTECTOMY: A POPULATION-BASED INVERSE-PROBABILITY WEIGHTED ANALYSIS
    Chung, Rainjade
    Anderson, Christopher
    McKiernan, James
    Faiena, Izak
    JOURNAL OF UROLOGY, 2021, 206 : E907 - E908
  • [2] Histological variants of non-muscle invasive bladder cancer: Survival outcomes of radical cystectomy vs. bladder preservation therapy
    Dursun, Furkan
    Elshabrawy, Ahmed
    Wang, Hanzhang
    Wu, Shenghui
    Liss, Michael A.
    Kaushik, Dharam
    Grosser, Daniel
    Svatek, Robert S.
    Mansour, Ahmed M.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (06) : 275.e1 - 275.e10
  • [3] Contemporary utilization trends and survival outcomes in patients undergoing radical cystectomy and bladder preservation therapy for muscle invasive bladder cancer
    Cahn, David
    Handorf, Elizabeth
    Nordsiek, Michael
    Churilla, Thomas M.
    Horwitz, Eric M.
    Ristau, Benjamin T.
    Chen, David Y. T.
    Viterbo, Rosalia
    Greenberg, Richard Evan
    Kutikov, Alexander
    Uzzo, Robert G.
    Smaldone, Marc C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [4] CONTEMPORARY UTILIZATION TRENDS AND SURVIVAL OUTCOMES IN PATIENTS UNDERGOING RADICAL CYSTECTOMY AND BLADDER PRESERVATION THERAPY FOR MUSCLE INVASIVE BLADDER CANCER
    Cahn, David
    Handorf, Elizabeth
    Nordsiek, Michael
    Churilla, Thomas
    Horwitz, Eric
    Ristau, Benjamin
    Chen, David
    Vitebo, Rosalia
    Greenberg, Richard
    Kutikov, Alexander
    Uzzo, Robert
    Smaldone, Marc
    JOURNAL OF UROLOGY, 2016, 195 (04): : E649 - E649
  • [5] COMPARATIVE STUDY ON SURVIVAL OUTCOMES OF BLADDER PRESERVATION STRATEGIES IN OLDER POPULATION WITH MUSCLE-INVASIVE BLADDER CANCER: PARTIAL CYSTECTOMY VS. CHEMORADIATION
    Avudaiappan, Arjun Pon
    Prabhakar, Pushan
    Chandar, Jay
    Ozambela, Manuel
    Eldefrawy, Ahmed
    Manoharan, Murugesan
    JOURNAL OF UROLOGY, 2024, 211 (05): : E1255 - E1256
  • [6] Chemotherapy vs. immunotherapy as neoadjuvant therapies in cisplatin-eligible patients undergoing radical cystectomy for muscle invasive bladder cancer
    Nocera, L.
    Bandini, M.
    Basile, G.
    Moschini, M.
    Naidu, S. U.
    Rose, K. M.
    Li, R.
    Spiess, P.
    Necchi, A.
    EUROPEAN UROLOGY, 2023, 83
  • [8] Incidental prostate cancer in patients undergoing radical cystectomy for muscle invasive bladder cancer
    Lindenmeir, T.
    Liehr, U. B.
    Rau, O.
    Reiher, F.
    Allhoff, E. P.
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 220 - 220
  • [9] A comparative study of survival outcomes between partial and radical cystectomy in octogenarians with muscle-invasive bladder cancer
    Avudaiappan, Arjun Pon
    Prabhakar, Pushan
    Lusnia, Ciara
    Ganiyani, Mohmmad Arfat
    Rubens, Muni
    Garje, Rohan
    Eldefrawy, Ahmed
    Manoharan, Murugesan
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2024, 13 (08) : 1486 - 1497
  • [10] Contemporary Use Trends and Survival Outcomes in Patients Undergoing Radical Cystectomy or Bladder-Preservation Therapy for Muscle-Invasive Bladder Cancer
    Cahn, David B.
    Handorf, Elizabeth A.
    Ghiraldi, Eric M.
    Ristau, Benjamin T.
    Geynisman, Daniel M.
    Churilla, Thomas M.
    Horwitz, Eric M.
    Sobczak, Mark L.
    Chen, David Y. T.
    Viterbo, Rosalia
    Greenberg, Richard E.
    Kutikov, Alexander
    Uzzo, Robert G.
    Smaldone, Marc C.
    CANCER, 2017, 123 (22) : 4337 - 4345